EC
TRAW icon

EcoR1 Capital’s Traws Pharma TRAW Stock Holding History

EcoR1 Capital’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,129
Closed -$893K – 55
2018
Q4 		$893K Sell
1,129
-204
-15% -$348K 0.09% 49
2018
Q3 		$3.67M Hold
1,333
– – 0.33% 39
2018
Q2 		$3.03M Buy
+1,333
New +$3.87M 0.29% 30

Other funds holding TRAW

6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
TCP
Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PFGIA
Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

EcoR1 Capital's TRAW Position: Q1 2019 in Review

EcoR1 Capital sold out of Traws Pharma (TRAW) in Q1 2019, closing a stake of 1,129 shares — an estimated $893K sold.

EcoR1 Capital first reported a position in TRAW in Q2 2018 and held it in 3 quarters. The position peaked at $3.67M in Q3 2018. 12 funds tracked by Wall St. Rank hold TRAW as of Q1 2019.

  • EcoR1 Capital reported no remaining Traws Pharma position as of Q1 2019 after selling out during the quarter.
  • EcoR1 Capital sold 1,129 Traws Pharma shares in Q1 2019, an estimated $893K.
  • EcoR1 Capital first reported a position in Traws Pharma in Q2 2018 and held it in 3 quarters.
  • EcoR1 Capital's Traws Pharma position peaked at $3.67M in Q3 2018.
  • 12 funds tracked by Wall St. Rank held Traws Pharma as of Q1 2019.

Based on EcoR1 Capital's 13F filing for Q1 2019, filed 15 May 2019.